Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells

Biochemical Pharmacology

Volumn 85, Issue 2, 2013, Pages 173-185

  Thaler, R ^a   Spitzer, S ^a   Karlic, H ^a   Berger, C ^b   Klaushofer, K ^a   Varga, F ^a  

^a HANUSCH HOSPITAL   (Austria)

^b DANUBE HOSPITAL   (Austria)

Author keywords

Bisphosphonates; Epigenetic DNA methylation; FAS apoptosis; Ibandronate; Small GTPases

Indexed keywords

CASPASE; CELL DNA; DNA METHYLTRANSFERASE 1; FAS ANTIGEN; GUANOSINE TRIPHOSPHATASE; IBANDRONIC ACID; PROTEIN FARNESYLTRANSFERASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; ENZYME INHIBITION; ENZYME REGULATION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; ISOPRENYLATION; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; HUMANS; MALE; MICE; NEOPLASM PROTEINS; OSTEOSARCOMA; PROMOTER REGIONS, GENETIC; UP-REGULATION;

EID: 84872037789     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.10.016     Document Type: Article

References (87)

1. M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon Emerging anti-cancer molecular mechanisms of aminobisphosphonates Endocr Relat Cancer 13 2006 7 26
2. R. Baron, S. Ferrari, and R.G. Russell Denosumab and bisphosphonates: different mechanisms of action and effects Bone 48 2011 677 692
3. M.R. Graaf, D.J. Richel, C.J. van Noorden, and H.J. Guchelaar Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer Cancer Treat Rev 30 2004 609 641
4. Y. Kucukzeybek, G. Gorumlu, E. Cengiz, B. Karabulut, C. Sezgin, and H. Atmaca Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells J Int Med Res 38 2010 1663 1672
5. S.P. Luckman, D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, and M.J. Rogers Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J Bone Miner Res 13 1998 581 589
6. S. Nilsson, J. Huelsenbeck, and G. Fritz Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells Cancer Lett 304 2011 60 69
7. M.J. Rogers, J.C. Crockett, F.P. Coxon, and J. Monkkonen Biochemical and molecular mechanisms of action of bisphosphonates Bone 49 2011 34 41
8. K. Walker, and M.F. Olson Targeting Ras Rho GTPases as opportunities for cancer therapeutics Curr Opin Genet Dev 15 2005 62 68
9. J.E. Dunford, M.J. Rogers, F.H. Ebetino, R.J. Phipps, and F.P. Coxon Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases J Bone Miner Res 21 2006 684 694
10. A.A. Reszka, J. Halasy-Nagy, and G.A. Rodan Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation Mol Pharmacol 59 2001 193 202
11. H.L. Benford, J.C. Frith, S. Auriola, J. Monkkonen, and M.J. Rogers Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs Mol Pharmacol 56 1999 131 140
12. D. Vigil, J. Cherfils, K.L. Rossman, and C.J. Der Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy Nat Rev Cancer 10 2010 842 857
13. F. Calvo, L. Agudo-Ibanez, and P. Crespo The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies Bioessays 32 2010 412 421
14. Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi RAS oncogenes: weaving a tumorigenic web Nat Rev Cancer 11 2011 761 774
15. C. Montagut, and J. Settleman Targeting the RAF-MEK-ERK pathway in cancer therapy Cancer Lett 283 2009 125 134
16. I.M. Ahearn, K. Haigis, D. Bar-Sagi, and M.R. Philips Regulating the regulator: post-translational modification of RAS Nat Rev Mol Cell Biol 13 2012 39 51
17. C. Gazin, N. Wajapeyee, S. Gobeil, C.M. Virbasius, and M.R. Green An elaborate pathway required for Ras-mediated epigenetic silencing Nature 449 2007 1073 1077
18. S.K. Patra, and M. Szyf DNA methylation-mediated nucleosome dynamics and oncogenic Ras signaling: insights from FAS, FAS ligand and RASSF1A FEBS J 275 2008 5217 5235
19. R. Thaler, M. Agsten, S. Spitzer, E.P. Paschalis, H. Karlic, and K. Klaushofer Homocysteine suppresses the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation J Biol Chem 286 2011 5578 5588
20. G.P. Delcuve, M. Rastegar, and J.R. Davie Epigenetic control J Cell Physiol 219 2009 243 250
21. K. Huang, and G. Fan DNA methylation in cell differentiation and reprogramming: an emerging systematic view Regen Med 5 2010 531 544
22. M.M. Suzuki, and A. Bird DNA methylation landscapes: provocative insights from epigenomics Nat Rev Genet 9 2008 465 476
23. I. Petak, R.P. Danam, D.M. Tillman, R. Vernes, S.R. Howell, and L. Berczi Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma Cell Death Differ 10 2003 211 217
24. S. Santourlidis, U. Warskulat, A.R. Florl, S. Maas, T. Pulte, and J. Fischer Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma Mol Carcinog 32 2001 36 43
25. J. Reibenwein, D. Pils, P. Horak, B. Tomicek, G. Goldner, and N. Worel Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance Prostate 67 2007 427 432
26. M. Sasaki, Y. Tanaka, G. Perinchery, A. Dharia, I. Kotcherguina, and S. Fujimoto Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer J Natl Cancer Inst 94 2002 384 390
27. J.A. Brinkman, and D. El-Ashry ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers J Mammary Gland Biol Neoplasia 14 2009 67 78
28. M.J. Fackler, C.B. Umbricht, D. Williams, P. Argani, L.A. Cruz, and V.F. Merino Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence Cancer Res 71 2011 6195 6207
29. F. Vesuna, A. Lisok, B. Kimble, J. Domek, Y. Kato, and P. van der Groep Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha Oncogene 31 27 2011 3223 3234
30. Y. Oki, and J.P. Issa Epigenetic mechanisms in AML-a target for therapy Cancer Treat Res 145 2010 19 40
31. J. Wu, and G.S. Wood Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma Arch Dermatol 147 2011 443 449
32. O. Hopfer, M. Komor, I.S. Koehler, C. Freitag, M. Schulze, and D. Hoelzer Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms Leuk Res 33 2009 434 442
33. H. Karlic, R. Reitermaier, V. Ghanim, H. Hermann, R. Thaler, and S. Spitzer 5-Azacytidine and decitabine induce demethylation and re-expression of FAS (CD95) and promoter apoptosis in neoplastic cells in acute myeloid leukemia (AML) Blood 118 2011 3463 AHS Annual Meeting Abstracts
34. V. Ghanim, H. Herrmann, G. Heller, B. Peter, E. Hadzijusufovic, and K. Blatt 5-Azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand Blood 119 2012 4242 4252
35. H. Fujita, K. Kurokawa, T. Ogino, M. Ono, M. Yamamoto, and T. Oka Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-kappaB ligand and apoptosis in mesenchymal stem cells Basic Clin Pharmacol Toxicol 109 2011 78 84
36. J. Wang, and P.H. Stern Dose-dependent differential effects of risedronate on gene expression in osteoblasts Biochem Pharmacol 81 2011 1036 1042
37. A. Corrado, A. Neve, N. Maruotti, A. Gaudio, A. Marucci, and F.P. Cantatore Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures Clin Exp Rheumatol 28 2010 873 879
38. M.W. Pfaffl A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res 29 2001 e45
39. R. Thaler, H. Karlic, S. Spitzer, K. Klaushofer, and F. Varga Extra-cellular matrix suppresses expression of the apoptosis mediator Fas by epigenetic DNA methylation Apoptosis 15 2010 728 737
40. M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Postlberger, and C. Menzel Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679 691
41. M. Pazianas, B. Abrahamsen, P.A. Eiken, R. Eastell, and R.G. Russell Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register Based Cohort Study Osteoporos Int 23 11 2012 2693 2701
42. N. Bundred Antiresorptive therapies in oncology and their effects on cancer progression Cancer Treat Rev 38 6 2012 776 786
43. M. Pazianas, and R.G. Russell Potential therapeutic effects of oral bisphosphonates on the intestine Ann N Y Acad Sci 1240 2011 E19 E25
44. P. Rodrigues, F.O. Hering, and A. Meller Adjuvant effect of IV clodronate on the delay of bone metastasis in high-risk prostate cancer patients: a prospective study Cancer Res Treat 43 2011 231 235
45. F.R.L.E.B. Daubine, M. Marquez, S. Nilsson, T. Schroder, and A.R. Holmberg Treatment of bone metastasis in prostate cancer: efficacy of a novel polybisphosphonate Anticancer Res 31 2011 4141 4145
46. C.R. Cardwell, C.C. Abnet, P. Veal, C.M. Hughes, M.M. Cantwell, and L.J. Murray Exposure to oral bisphosphonates and risk of cancer Int J Cancer 131 5 2012 E717 E725
47. I.A. Prior, and J.F. Hancock Ras trafficking, localization and compartmentalized signalling Semin Cell Dev Biol 23 2 2012 145 153
48. J.E. Fisher, M.J. Rogers, J.M. Halasy, S.P. Luckman, D.E. Hughes, and P.J. Masarachia Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proc Natl Acad Sci U S A 96 1999 133 138
49. M.F. Moreau, C. Guillet, P. Massin, S. Chevalier, H. Gascan, and M.F. Basle Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro Biochem Pharmacol 73 2007 718 723
50. H. Monkkonen, S. Auriola, P. Lehenkari, M. Kellinsalmi, I.E. Hassinen, and J. Vepsalainen A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates Br J Pharmacol 147 2006 437 445
51. M.J. Rogers, K.M. Chilton, F.P. Coxon, J. Lawry, M.O. Smith, and S. Suri Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism J Bone Miner Res 11 1996 1482 1491
52. S.P. Luckman, F.P. Coxon, F.H. Ebetino, R.G. Russell, and M.J. Rogers Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages J Bone Miner Res 13 1998 1668 1678
53. F.P. Coxon, H.L. Benford, R.G. Russell, and M.J. Rogers Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs Mol Pharmacol 54 1998 631 638
54. J.M. Halasy-Nagy, G.A. Rodan, and A.A. Reszka Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis Bone 29 2001 553 559
55. M. Sato, and W. Grasser Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy J Bone Miner Res 5 1990 31 40
56. V. Breuil, F. Cosman, L. Stein, W. Horbert, J. Nieves, and V. Shen Human osteoclast formation and activity in vitro: effects of alendronate J Bone Miner Res 13 1998 1721 1729
57. P. Ralph, M.A. Moore, and K. Nilsson Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines J Exp Med 143 1976 1528 1533
58. L.I. Plotkin, R.S. Weinstein, A.M. Parfitt, P.K. Roberson, S.C. Manolagas, and T. Bellido Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin J Clin Invest 104 1999 1363 1374
59. L.I. Plotkin, S.C. Manolagas, and T. Bellido Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs Bone 39 2006 443 452
60. G.G. Reinholz, B. Getz, L. Pederson, E.S. Sanders, M. Subramaniam, and J.N. Ingle Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts Cancer Res 60 2000 6001 6007
61. G.I. Im, S.A. Qureshi, J. Kenney, H.E. Rubash, and A.S. Shanbhag Osteoblast proliferation and maturation by bisphosphonates Biomaterials 25 2004 4105 4115
62. F. von Knoch, C. Jaquiery, M. Kowalsky, S. Schaeren, C. Alabre, and I. Martin Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells Biomaterials 26 2005 6941 6949
63. M. Ehrlich DNA methylation in cancer: too much, but also too little Oncogene 21 2002 5400 5413
64. M.F. Fraga, and M. Esteller Epigenetics and aging: the targets and the marks Trends Genet 23 2007 413 418
65. A.S. Wilson, B.E. Power, and P.L. Molloy DNA hypomethylation and human diseases Biochim Biophys Acta 1775 2007 138 162
66. R. Ebert, S. Zeck, R. Krug, J. Meissner-Weigl, D. Schneider, and L. Seefried Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation Bone 44 2009 858 864
67. F.P. Coxon, M.H. Helfrich, R. Van't Hof, S. Sebti, S.H. Ralston, and A. Hamilton Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298 J Bone Miner Res 15 2000 1467 1476
68. S.W. Lane, S. De Vita, K.A. Alexander, R. Karaman, M.D. Milsom, and A.M. Dorrance Rac signaling in osteoblastic cells is required for normal bone development but is dispensable for hematopoietic development Blood 119 2012 736 744
69. B. Kubista, K. Trieb, F. Sevelda, C. Toma, F. Arrich, and P. Heffeter Anticancer effects of zoledronic acid against human osteosarcoma cells J Orthop Res 24 2006 1145 1152
70. A.M. Forsea, C. Muller, C. Riebeling, C.E. Orfanos, and C.C. Geilen Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells Br J Cancer 91 2004 803 810
71. M.V. Lee, E.M. Fong, F.R. Singer, and R.S. Guenette Bisphosphonate treatment inhibits the growth of prostate cancer cells Cancer Res 61 2001 2602 2608
72. Y.S. Lin, J. Park, J.W. De Schutter, X.F. Huang, A.M. Berghuis, and M. Sebag Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells J Med Chem 55 2012 3201 3215
73. Y. Zhang, R. Cao, F. Yin, M.P. Hudock, R.T. Guo, and K. Krysiak Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation J Am Chem Soc 131 2009 5153 5162
74. S.A. Armstrong, V.C. Hannah, J.L. Goldstein, and M.S. Brown CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB J Biol Chem 270 1995 7864 7868
75. A.D. Basso, P. Kirschmeier, and W.R. Bishop Lipid posttranslational modifications. Farnesyl transferase inhibitors J Lipid Res 47 2006 15 31
76. P.K. Epling-Burnette, and T.P. Loughran Jr. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib Expert Opin Investig Drugs 19 2010 689 698
77. B.K. Law, P. Norgaard, L. Gnudi, B.B. Kahn, H.S. Poulson, and H.L. Moses Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway J Biol Chem 274 1999 4743 4748
78. M.M. Moasser, and N. Rosen The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer Breast Cancer Res Treat 73 2002 135 144
79. D.B. Whyte, P. Kirschmeier, T.N. Hockenberry, I. Nunez-Oliva, L. James, and J.J. Catino K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J Biol Chem 272 1997 14459 14464
80. F.L. Zhang, P. Kirschmeier, D. Carr, L. James, R.W. Bond, and L. Wang Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I J Biol Chem 272 1997 10232 10239
81. Y. Ohtsuka, A. Manabe, H. Kawasaki, D. Hasegawa, Y. Zaike, and S. Watanabe RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro Blood 106 2005 3134 3141
82. A. Kaneda, K. Wakazono, T. Tsukamoto, N. Watanabe, Y. Yagi, and M. Tatematsu Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers Cancer Res 64 2004 6410 6415
83. A. Carnero The PKB/AKT pathway in cancer Curr Pharm Des 16 2010 34 44
84. J. Omerovic, A.J. Laude, and I.A. Prior Ras proteins: paradigms for compartmentalised and isoform-specific signalling Cell Mol Life Sci 64 2007 2575 2589
85. D. Nojima, L.C. Li, A. Dharia, G. Perinchery, L. Ribeiro-Filho, and T.S. Yen CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma Cancer 92 2001 2076 2083
86. H. Kinoshita, Y. Shi, C. Sandefur, L.F. Meisner, C. Chang, and A. Choon Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer Cancer Res 60 2000 3623 3630
87. R.E. Coleman, H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, and M. Keane Breast-cancer adjuvant therapy with zoledronic acid N Engl J Med 365 2011 1396 1405